Corcept Therapeutics (CORT) 5.51 $CORT
Corcept (CORT) Reports Early Breast Cancer Data on Korlym
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 4:06PM CDT
Corcept (CORT) released preliminary efficacy data from a phase I/II study on Korlym for the treatment of treat triple-negative breast cancer (TNBC).
PFE: 35.28 (-0.03), BMY: 72.74 (+0.01), CORT: 5.51 (+0.04), CELG: 103.62 (-2.51)
Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program
Marketwired - Thu Jun 02, 3:05PM CDT
MENLO PARK, CA--(Marketwired - Jun 2, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT)
CORT: 5.51 (+0.04)
Corcept beats 1Q profit forecasts
Automated Insights - Tue May 03, 3:35PM CDT
MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Tuesday reported a loss of $19,000 in its first quarter.
CORT: 5.51 (+0.04)
Corcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update
Marketwired - Tue May 03, 3:05PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT)
CORT: 5.51 (+0.04)
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
Marketwired - Fri Apr 29, 7:30AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2016. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORT: 5.51 (+0.04)
Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushing's Syndrome and Solid-Tumor Cancers
Marketwired - Thu Apr 28, 3:05PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today released data supporting the clinical advancement of its proprietary, selective cortisol modulator, CORT125134. The company has begun recruiting patients for a Phase 1/2 trial of the compound to treat patients with solid-tumor cancers. It also expects to begin recruiting patients for a Phase 2 study of CORT125134 to treat patients with Cushing's syndrome this quarter.
CORT: 5.51 (+0.04)
Corcept Therapeutics (CORT) Jumps: Stock Moves Up 9.6%
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 7:15AM CDT
Corcept Therapeutics Incorporated (CORT) shares rose almost 10% in the last trading session.
CALA: 4.83 (-0.22), CORT: 5.51 (+0.04)
Valeant CEO Gets Subpoena from Senate Aging Committee
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:45PM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) dropped 7.2% after the company's CEO received a subpoena from the Senate Aging Committee amid the ongoing mess.
VRX: 24.73 (-0.75), ARQL: 1.82 (+0.04), SCMP: 11.89 (-0.08), CORT: 5.51 (+0.04)
Aerie Starts Dosing in Registration Trial Mercury 2 on Roclatan
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:25PM CDT
Aerie Pharmaceuticals, Inc. (AERI) announced the initiation of dosing in the second phase III registration trial, Mercury 2, on its pipeline candidate, Roclatan 0.02%/0.005%.
SCMP: 11.89 (-0.08), AERI: 18.65 (-0.16), CORT: 5.51 (+0.04)
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
SYN: 1.84 (+0.03), GERN: 2.78 (-0.03), EPZM: 11.88 (-0.38), CORT: 5.51 (+0.04)
Galmed Pharmaceuticals (GLMD) Jumps: Stock Rises 7.9%
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 7:15AM CDT
Galmed Pharmaceuticals Ltd. (GLMD) shares rose almost 8% in the last trading session.
GLMD: 4.34 (-0.02), CORT: 5.51 (+0.04)
4 Surging Stocks Brokers Love in the Healthcare Sector
Arpita Dutt - Zacks Investment Research - Mon Mar 28, 8:16AM CDT
These four stocks are holding their own in a sector that has been in the news for the wrong reasons and have surged more than 10% in the last 4 weeks.
JNJ: 116.87 (-0.13), VRX: 24.73 (-0.75), SYN: 1.84 (+0.03), GERN: 2.78 (-0.03), AMGN: 154.77 (-2.01), EPZM: 11.88 (-0.38), CORT: 5.51 (+0.04)
Roche Files for FDA Approval of Elecsys BRAHMS Assay
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 8:30AM CDT
Roche Holdings, Inc. (RHHBY) announced that the company has submitted the Elecsys BRAHMS PCT (Procalcitonin) assay for Premarket Notification (510k) with the FDA
ARQL: 1.82 (+0.04), SCMP: 11.89 (-0.08), CORT: 5.51 (+0.04)
Can The Uptrend Continue for Corcept Therapeutics (CORT)?
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 9:18AM CDT
Investors certainly have to be happy with Corcept Therapeutics Incorporated (CORT) and its short term performance
CORT: 5.51 (+0.04)
Valeant to Get a New CEO Amid Turmoil, Ackman on Board
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 11:40AM CDT
Valeant Pharmaceuticals International, Inc.'s (VRX) current chief executive officer (CEO) J. Michael Pearson has recently decided to step down.
VRX: 24.73 (-0.75), ARQL: 1.82 (+0.04), SCMP: 11.89 (-0.08), CORT: 5.51 (+0.04)
Valeant Pharmaceuticals (VRX) Jumps: Stock Adds 7.4%
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 7:00AM CDT
Valeant (VRX) was a big mover last session, with its shares rising over 7% on the day.
VRX: 24.73 (-0.75), CORT: 5.51 (+0.04)
McKesson (MCK) to Restructure Operations, Lower Headcount
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 4:28PM CDT
McKesson Corporation (MCK) announced that management has undertaken a restructuring plan to lower its operating costs amid challenging business operations.
MCK: 185.62 (-1.26), ARQL: 1.82 (+0.04), SCMP: 11.89 (-0.08), CORT: 5.51 (+0.04)
3 Hedge Funds That Lost Hundreds of Millions on Valeant Stock
Zacks Equity Research - Zacks Investment Research - Thu Mar 17, 1:16PM CDT
Valeant Pharmaceuticals International Inc.'s (VRX) announcement of fourth quarter results and lowering of annual and quarterly guidance left its major institutional holders fuming and in the red.
VRX: 24.73 (-0.75), SCMP: 11.89 (-0.08), CORT: 5.51 (+0.04)
Forget Valeant, Buy These 5 Drug Stocks Instead
Arpita Dutt - Zacks Investment Research - Thu Mar 17, 9:10AM CDT
It's time to focus on drug stocks with interesting pipelines, good prospects and favorable Zacks Ranks.
SGYP: 4.05 (+0.05), VRX: 24.73 (-0.75), SCMP: 11.89 (-0.08), ARIA: 8.26 (-0.16), ENTA: 22.97 (-0.56), CORT: 5.51 (+0.04)
Corcept (CORT) Reports Early Breast Cancer Data on Korlym
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 4:06PM CDT
Corcept (CORT) released preliminary efficacy data from a phase I/II study on Korlym for the treatment of treat triple-negative breast cancer (TNBC).
PFE: 35.28 (-0.03), BMY: 72.74 (+0.01), CORT: 5.51 (+0.04), CELG: 103.62 (-2.51)
Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program
Marketwired - Thu Jun 02, 3:05PM CDT
MENLO PARK, CA--(Marketwired - Jun 2, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT)
CORT: 5.51 (+0.04)
Corcept beats 1Q profit forecasts
Automated Insights - Tue May 03, 3:35PM CDT
MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Tuesday reported a loss of $19,000 in its first quarter.
CORT: 5.51 (+0.04)
Corcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update
Marketwired - Tue May 03, 3:05PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT)
CORT: 5.51 (+0.04)
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
Marketwired - Fri Apr 29, 7:30AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2016. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORT: 5.51 (+0.04)
Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushing's Syndrome and Solid-Tumor Cancers
Marketwired - Thu Apr 28, 3:05PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today released data supporting the clinical advancement of its proprietary, selective cortisol modulator, CORT125134. The company has begun recruiting patients for a Phase 1/2 trial of the compound to treat patients with solid-tumor cancers. It also expects to begin recruiting patients for a Phase 2 study of CORT125134 to treat patients with Cushing's syndrome this quarter.
CORT: 5.51 (+0.04)
Corcept Therapeutics (CORT) Jumps: Stock Moves Up 9.6%
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 7:15AM CDT
Corcept Therapeutics Incorporated (CORT) shares rose almost 10% in the last trading session.
CALA: 4.83 (-0.22), CORT: 5.51 (+0.04)
Valeant CEO Gets Subpoena from Senate Aging Committee
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:45PM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) dropped 7.2% after the company's CEO received a subpoena from the Senate Aging Committee amid the ongoing mess.
VRX: 24.73 (-0.75), ARQL: 1.82 (+0.04), SCMP: 11.89 (-0.08), CORT: 5.51 (+0.04)
Aerie Starts Dosing in Registration Trial Mercury 2 on Roclatan
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:25PM CDT
Aerie Pharmaceuticals, Inc. (AERI) announced the initiation of dosing in the second phase III registration trial, Mercury 2, on its pipeline candidate, Roclatan 0.02%/0.005%.
SCMP: 11.89 (-0.08), AERI: 18.65 (-0.16), CORT: 5.51 (+0.04)
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
SYN: 1.84 (+0.03), GERN: 2.78 (-0.03), EPZM: 11.88 (-0.38), CORT: 5.51 (+0.04)
Galmed Pharmaceuticals (GLMD) Jumps: Stock Rises 7.9%
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 7:15AM CDT
Galmed Pharmaceuticals Ltd. (GLMD) shares rose almost 8% in the last trading session.
GLMD: 4.34 (-0.02), CORT: 5.51 (+0.04)
4 Surging Stocks Brokers Love in the Healthcare Sector
Arpita Dutt - Zacks Investment Research - Mon Mar 28, 8:16AM CDT
These four stocks are holding their own in a sector that has been in the news for the wrong reasons and have surged more than 10% in the last 4 weeks.
JNJ: 116.87 (-0.13), VRX: 24.73 (-0.75), SYN: 1.84 (+0.03), GERN: 2.78 (-0.03), AMGN: 154.77 (-2.01), EPZM: 11.88 (-0.38), CORT: 5.51 (+0.04)
Roche Files for FDA Approval of Elecsys BRAHMS Assay
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 8:30AM CDT
Roche Holdings, Inc. (RHHBY) announced that the company has submitted the Elecsys BRAHMS PCT (Procalcitonin) assay for Premarket Notification (510k) with the FDA
ARQL: 1.82 (+0.04), SCMP: 11.89 (-0.08), CORT: 5.51 (+0.04)
Can The Uptrend Continue for Corcept Therapeutics (CORT)?
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 9:18AM CDT
Investors certainly have to be happy with Corcept Therapeutics Incorporated (CORT) and its short term performance
CORT: 5.51 (+0.04)
Valeant to Get a New CEO Amid Turmoil, Ackman on Board
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 11:40AM CDT
Valeant Pharmaceuticals International, Inc.'s (VRX) current chief executive officer (CEO) J. Michael Pearson has recently decided to step down.
VRX: 24.73 (-0.75), ARQL: 1.82 (+0.04), SCMP: 11.89 (-0.08), CORT: 5.51 (+0.04)
Valeant Pharmaceuticals (VRX) Jumps: Stock Adds 7.4%
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 7:00AM CDT
Valeant (VRX) was a big mover last session, with its shares rising over 7% on the day.
VRX: 24.73 (-0.75), CORT: 5.51 (+0.04)
McKesson (MCK) to Restructure Operations, Lower Headcount
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 4:28PM CDT
McKesson Corporation (MCK) announced that management has undertaken a restructuring plan to lower its operating costs amid challenging business operations.
MCK: 185.62 (-1.26), ARQL: 1.82 (+0.04), SCMP: 11.89 (-0.08), CORT: 5.51 (+0.04)
3 Hedge Funds That Lost Hundreds of Millions on Valeant Stock
Zacks Equity Research - Zacks Investment Research - Thu Mar 17, 1:16PM CDT
Valeant Pharmaceuticals International Inc.'s (VRX) announcement of fourth quarter results and lowering of annual and quarterly guidance left its major institutional holders fuming and in the red.
VRX: 24.73 (-0.75), SCMP: 11.89 (-0.08), CORT: 5.51 (+0.04)
Forget Valeant, Buy These 5 Drug Stocks Instead
Arpita Dutt - Zacks Investment Research - Thu Mar 17, 9:10AM CDT
It's time to focus on drug stocks with interesting pipelines, good prospects and favorable Zacks Ranks.
SGYP: 4.05 (+0.05), VRX: 24.73 (-0.75), SCMP: 11.89 (-0.08), ARIA: 8.26 (-0.16), ENTA: 22.97 (-0.56), CORT: 5.51 (+0.04)
